Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Recursion Pharmaceuticals (RXRX), a trailblazer in AI-powered drug discovery, recently acquired its competitor, Exscientia, in a strategic move that solidifies its leading position in the industry.

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

Important messages require accurate transmission. Big genes are especially challenging. During processing, introns (non-coding elements) are snipped out and exons (coding segments) pasted together to ...

Chris Gibson, Recursion Pharmaceuticals CEO, joins 'Closing Bell Overtime' to talk its partnership with Nvidia, its investors day, drug discovery and more. Got a confidential news tip? We want to hear ...